DECOGLURANT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H11F6N5
Molecular Weight	447.336
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=C(C=C1)C#CC2=C3N=C(C=C(N3N=C2)C(F)(F)F)C4=CC=C(C=C4)C(F)(F)F

InChI

InChIKey=DMJHZVARRXJSEG-UHFFFAOYSA-N

InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)

HIDE SMILES / InChI

Molecular Formula	C21H11F6N5
Molecular Weight	447.336
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30447328 | https://adisinsight.springer.com/drugs/800034342

Decoglurant is a negative allosteric modulator of the mGlu2 and mGlu receptors developed by Roche. Decoglurant was investigated in a phase 2 clinical trials in patients with major depressive disorder. Negative results were reported and the development was discontinued in 2015.

Originator

Approval Year

C_max

Value	Dose	Analyte	Population
143 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32663909/	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DECOGLURANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
532 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32663909/	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DECOGLURANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
835 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32663909/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DECOGLURANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.	2019-02	30447328

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:08:01 GMT 2025` Edited by `admin` on `Mon Mar 31 21:08:01 GMT 2025`
Record UNII	5VX4P0JKC5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DECOGLURANT

Official Name

English

DECOGLURANT [USAN]

Preferred Name

English

RO-4995819

Code

English

2-PYRIDINAMINE, 5-(2-(7-(TRIFLUOROMETHYL)-5-(4-(TRIFLUOROMETHYL)PHENYL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)ETHYNYL)-

Systematic Name

English

2-PYRIDINAMINE, 5-((7-(TRIFLUOROMETHYL)-5-(4-(TRIFLUOROMETHYL)PHENYL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)ETHYNYL)-

Systematic Name

English

decoglurant [INN]

Common Name

English

Decoglurant [WHO-DD]

Common Name

English

5-(2-{7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)pyridin-2-amine

Systematic Name

English

RO4995819

Code

English

Code System Code Type Description

SMS_ID

300000034094